The trial was designed to explore the safety and tolerability of PBT2, and its effects on the mechanism and progression of the disease, by investigating biomarkers of Alzheimer’s disease as well as measures of cognition. The final follow-up visits for patients will be completed before the end of December. The company said that the trial is on track to deliver results in the first quarter of 2008.
Steven Targum, chief medical advisor to Prana, said: “We are delighted to have completed dosing of patients. Given the lack of drug-related serious adverse events and the positive independent Data Safety Monitoring Board reports, the drug has shown itself to be well tolerated. Indeed, there were no treatment-related withdrawals from the trial and a very high level of patient compliance which is also very pleasing.”